bioAffinity Technologies IncNASDAQ:BIAF
- LAST PRICE1.8000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.7300/ 1
- Ask / Lots1.8000/ 1
- Open / Previous Close1.7750 / 1.8000
- Day Range
- 52 Week Range
- Volume1,191
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BIAF |
|---|---|---|
| 10:10 ET | 300 | 1.79 |
| 10:24 ET | 133 | 1.72 |
| 10:32 ET | 100 | 1.735 |
| 10:53 ET | 100 | 1.755 |
| 11:18 ET | 175 | 1.8 |
Mar 28, 2023
Mar 24, 2023
bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023, from 8:00AM ET on Friday Mar 24, 2023 by Business Wire
8:00AM ET on Friday Mar 24, 2023 by Business Wire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
bioAffinity Technologies Inc | 15.1M | 0.0x | --- |
Modular Medical Inc | 15.7M | -1.0x | --- |
Femasys Inc | 13.6M | -1.2x | --- |
Pressure Biosciences Inc | 14.6M | -0.6x | --- |
Innovative Eyewear Inc | 12.8M | 0.0x | --- |
Sharps Technology Inc | 11.3M | -2.0x | --- |
Company Information
bioAffinity Technologies, Inc. is a biotechnology company. The Company is focused on addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as a targeted cancer treatment. The Company develops noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Its lead product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. Through its wholly owned subsidiary, OncoSelect Therapeutics, LLC, the Company’s research is engaged in the discoveries and advancement of cancer therapeutics that specifically and selectively target cancer cells. It is focused on expanding its platform technologies in developing tests that detect and therapies that target various types of cancer and potentially other diseases.
Contact Information
- Headquarters
- 22211 West Interstate-10, Suite 1206SAN ANTONIO, TX, United States 78257
- Phone
- 210-698-5334
- Fax
- 916-443-1908
Executives
- Executive Chairman of the Board
- Steven Girgenti
- President, Chief Executive Officer, Founder, Director
- Maria Zannes
- Chief Financial Officer
- Michael Edwards
- Executive Vice President, Chief Science and Medical Officer
- Vivienne Rebel
- Executive Vice President, General Counsel, Secretary
- Timothy Zannes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.1M |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | 8.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | --- |
Book Value | $-4.31 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
